November 10, 2021

 

Via EDGAR Transmission

 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Jane Park

 

	Re:	Rhythm Pharmaceuticals, Inc.
		Registration Statement on Form S-3
		Filed November 2, 2021
		Registration No. 333-260689

 

Ladies and Gentlemen:

 

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on November 15, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Rhythm Pharmaceuticals, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Wesley C. Holmes of Latham & Watkins LLP, counsel to the Company, at (617) 948-6027, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

 

		Sincerely yours,
		Rhythm Pharmaceuticals, Inc.
		By:	/s/ Hunter Smith
			Hunter Smith
			Chief Financial Officer
cc:	Peter N. Handrinos
	Wesley C. Holmes